Year None202420232022202120202019201820172016 August 27, 2024 Medicenna Announces Upcoming Presentations at The Promise of Interleukin-2 Therapy Conference Go to August 15, 2024 Medicenna Strengthens Board of Directors with Appointment of Karim Lalji Go to August 1, 2024 Medicenna Reports First Quarter Fiscal 2025 Financial Results and Announces First Complete Responder with MDNA11 Monotherapy Go to June 27, 2024 Medicenna Therapeutics Reports Fiscal Year 2024 Financial Results and Operational Highlights Go to June 26, 2024 Medicenna Announces EMA Approval of its Clinical Trial Application to Expand its Phase 1/2 ABILITY-1 Study to Europe Go to June 3, 2024 Medicenna Reports Significant Survival Benefit in Patients with Recurrent Glioblastoma Following Treatment with Bizaxofusp When Compared to a Matched External Control Arm at the 2024 ASCO Annual Meeting Go to Pagination First page « first Previous page ‹ previous Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Next page next › Last page last »
August 27, 2024 Medicenna Announces Upcoming Presentations at The Promise of Interleukin-2 Therapy Conference Go to
August 1, 2024 Medicenna Reports First Quarter Fiscal 2025 Financial Results and Announces First Complete Responder with MDNA11 Monotherapy Go to
June 27, 2024 Medicenna Therapeutics Reports Fiscal Year 2024 Financial Results and Operational Highlights Go to
June 26, 2024 Medicenna Announces EMA Approval of its Clinical Trial Application to Expand its Phase 1/2 ABILITY-1 Study to Europe Go to
June 3, 2024 Medicenna Reports Significant Survival Benefit in Patients with Recurrent Glioblastoma Following Treatment with Bizaxofusp When Compared to a Matched External Control Arm at the 2024 ASCO Annual Meeting Go to
